___

• American Diabetes Association, 2011. Standards of Medical Care in Diabetes-2011. Diabetes Care. 34, 11-61.
• Bakris, G.L., Weir, M.R., 2003. Achieving goal blood pressure in patients with type 2 diabetes: Conventional versus fixed -Dose combination Approaches. J. Clin. Hypertens. 5, 202-209.
• Bostom, A.G., Silbershatz, H., Rosenberg, I.R., Selhub, J., D’Agostino, R.B.., Wolf, P.A., Jacques, P.F., Wilson, P.W., 1999. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med. 159, 1077-80.
• Castelli, W.P., 1988. Cholesterol and lipids in the risk of coronary artery disease-the framingham heart study. Can. J. Cardiol. 4, 5-10.
• Chobanian, A., Bakris, G., Black, H., Cushman, W., Green, L., Izzo, J., Jones, D., Materson, B., Oparil, S., Wright, J., Roccella, E., 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 289, 2560-2572.
• Cholesterol Treatment Trialists Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 376, 1670-1681.
• Conroy, R.M.., Pyorala, K., Fitzgerald, A.P., Sans, S., Menotti, A., De Backer, G., De Bacquer, D., Ducimetiére, P., Joulassilahti, P., Keil, U., Niolstad, I., Oganov, R.G., Thomsen, T., Tunstall-Pedoe, H., Tverdal, A., Wedel, H., Whincup, P., Wilhelmsen, L., Graham, I.M., 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart. J. 24, 987-1003.
• Cuspidi, C., Mancia, G., Ambrosioni, E., Pessina, A., Trimarco, B and Zanchetti, A., 2004. Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: Results from the assessment prognostic risk observational survey (APROS). J. Hum. Hypertens. 18, 891-8
• Eberhard, R., 2007. Total Cardiovascular Risk Management. Am. J. Cardiol. 100, 53-60.
• Ertaş, F.S., 2007. Editorial comment: 2007 European Hypertension Guidelines. Arch. Turk. Soc. Cardiol. 35, 343-346.
• Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M.., Perk, J. Silvia, G., Priori, Pyorala, P.K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Reimer, W.S., Weissberg, P., Wood, D., Yarnell, J., Zamorano, J.L., 2007. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis. 194, 1-45.
• Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Gordon, D.J., Krauss, R.M., Savage, P.J., Smith, S.C., Spertus, J.A., Costa, F., 2005. Diagnosis and management of the metabolic syndrome. Circulation. 112, 2735-2752.
• Güleç, S., 2009. Kalp damar hastalıklarında global risk ve hedefler. Türk Kardiyol Dern. Arş. 37, 3-5.
• Jessani, S., Lip, G.Y.H., Barnett, A., Millane, T., 2007. The JBS-2 guidelines on prevention of cardiovascular disease in clinical practice: An opportunity missed. QJM. 100, 121-124.
• Kannel, W.B., 1996. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 275, 1571-1576.
• Keskin, Ö., Balcı, B., 2011. Diabetes mellitus ve kardiyovasküler komplikasyonlar. Kafkas J. Med. Sci. 1, 81-85.
• King, H., Aubert, R.E., Herman, W.H., 1998. Global burden of diabetes, 1995-2025. Diabetes Care. 21, 1414-1431.
• Kültürsay, H., 2011. Kardiyovasküler hastalık riski hesaplama yöntemleri. Türk. Kardiyol. Dern. Arş. 39, 6-13.
• Mancia, G., De Backer G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., Struijker Boudier, H.A., Zanchetti, A., 2007. 2007 Guidelines for the management of arterial hypertension. Eur. Heart J. 28, 1462-1536.
• National Heart, Lung, and Blood Institute, 2012. The Framingham Heart Study. Available from: http://www.framinghamheartstudy.org/about/ history.html.
• O’Donnell, C.J., Elosua, R., 2008. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol. 61, 299-310.
• Onat, A., Uğur, M., Tuncer, M., Ayhan, E., Kaya, Z., Küçükdurmaz, Z.,Bulur, S., Kaya, H., 2009. TEKHARF taramasında ölüm yaşı: 56,700 kişi-yıllık izlemede dönemsel eğilim ve bölgesel dağılım. Türk Kardiyol. Dern. Arş. 37, 155-160.
• Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., Harrap, S., Poulter, N., Marre, M., Cooper, M., Glasziou, P., Grobbee, D.E., Hamet, P., Heller, S., Liu, L.S., Mancia, G., Mogensen, C.E., Pan, C.Y., Rodgers, A., Williams, B., 2007. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 370, 829-840.
• Rajagopalan, S., Alemao, E., Finch, L., Yin, D., 2007. Impact of new Joint British Societies’ (JBS 2) guidelines on prevention of cardiovascular disease: Evaluation of serum total cholesterol goal achievement in UK clinical practice. Curr. Med. Res. Opin. 23, 2027-2034.
• Reiner, Z., Catapano, A.L., Backer, G.D., Graham, I., Taskinen, M.R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M., Durrington, P., Erdine, S., Halcox, F., Hobbs, R., Kjekshus, J., Filardi, P.P., Riccardi, G., Storey, R., 2011. ESC/EAS Guidelines for the management of Sonuç
• Kardiyovasküler hastalıklar halk sağlığını dünya genelinde tehdit etmeye devam etmektedir. Yüzyılımızda kardiyovasküler hastalıklar için global mortalite oranı % 30,9 ve hastalığın küresel yükü % 10,3 olarak hesaplanmıştır (Yusuf ve ark., 2001). Metabolik sendrom, insülin direnci, obezite, hiperglisemi, hipertansiyon gibi risk faktörleri kümelenmesini gösteren bir klinik antite olarak, tüm risk faktörleri ile tek tek mücadelenin önemini açıkça göstermektedir. Zira kardiyovasküler hastalıklara bağlı artan mortalite ve morbidite oranları için risk faktörlerinin tamamı ile etkin mücadele etmek gerekliliği apaçık ortadır.